<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10644273
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     01
    </month>
    <day>
     19
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     01
    </month>
    <day>
     19
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     19
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0003-4819
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       132
      </volume>
      <issue>
       2
      </issue>
      <pubdate>
       <year>
        2000
       </year>
       <month>
        Jan
       </month>
       <day>
        18
       </day>
      </pubdate>
     </journalissue>
     <title>
      Annals of internal medicine
     </title>
     <isoabbreviation>
      Ann. Intern. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Hepatocellular injury in a patient receiving rosiglitazone. A case report.
    </articletitle>
    <pagination>
     <medlinepgn>
      121-4
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Rosiglitazone maleate (Avandia, SmithKline Beecham, Philadelphia, Pennsylvania) is a new oral hypoglycemic agent approved for the treatment of type 2 diabetes. It acts primarily by increasing insulin sensitivity. In controlled trials, there has been no evidence of rosiglitazone-induced hepatocellular injury.
     </abstracttext>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To report a case of hepatocellular injury in a patient receiving rosiglitazone.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Case report.
     </abstracttext>
     <abstracttext label="SETTING" nlmcategory="METHODS">
      Community teaching hospital.
     </abstracttext>
     <abstracttext label="PATIENT" nlmcategory="METHODS">
      61-year-old man receiving rosiglitazone, 4 mg/d for 2 weeks.
     </abstracttext>
     <abstracttext label="INTERVENTION" nlmcategory="METHODS">
      Discontinuation of rosiglitazone therapy.
     </abstracttext>
     <abstracttext label="MEASUREMENTS" nlmcategory="METHODS">
      Clinical evaluation and assessment of liver function test results were done daily during hospitalization and periodically after discharge. The outpatient record was also reviewed.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      After receiving rosiglitazone for 2 weeks, the patient presented with anorexia, vomiting, and abdominal pain. Liver function tests revealed severe hepatocellular injury. Discontinuation of rosiglitazone therapy led to rapid improvement of liver function and resolution of symptoms.
     </abstracttext>
     <abstracttext label="CONCLUSION" nlmcategory="CONCLUSIONS">
      Rosiglitazone may be associated with hepatocellular injury. We believe that patients receiving rosiglitazone should have liver enzyme levels monitored earlier and more frequently than initially recommended.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Medicine, Easton Hospital, MCP-Hahnemann University, Pennsylvania 18042, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Al-Salman
      </lastname>
      <forename>
       J
      </forename>
      <initials>
       J
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Arjomand
      </lastname>
      <forename>
       H
      </forename>
      <initials>
       H
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kemp
      </lastname>
      <forename>
       D G
      </forename>
      <initials>
       DG
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Mittal
      </lastname>
      <forename>
       M
      </forename>
      <initials>
       M
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Case Reports
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Ann Intern Med
    </medlineta>
    <nlmuniqueid>
     0372351
    </nlmuniqueid>
    <issnlinking>
     0003-4819
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Hypoglycemic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Thiazoles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Thiazolidinediones
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      122320-73-4
     </registrynumber>
     <nameofsubstance>
      rosiglitazone
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2000 Oct 17;133(8):658
     </refsource>
     <pmid version="1">
      11033603
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Ann Intern Med. 2000 Sep 5;133(5):393-4
     </refsource>
     <pmid version="1">
      10979889
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="ErratumIn">
     <refsource>
      Ann Intern Med 2000 Aug 1;133(3):237
     </refsource>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Diabetes Mellitus, Type 2
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug-Induced Liver Injury
     </descriptorname>
     <qualifiername majortopicyn="N">
      diagnosis
     </qualifiername>
     <qualifiername majortopicyn="Y">
      etiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hypoglycemic Agents
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Liver
     </descriptorname>
     <qualifiername majortopicyn="N">
      enzymology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Liver Function Tests
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Monitoring, Physiologic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thiazoles
     </descriptorname>
     <qualifiername majortopicyn="Y">
      adverse effects
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="Y">
      Thiazolidinediones
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      1
     </month>
     <day>
      22
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      9
     </month>
     <day>
      8
     </day>
     <hour>
      11
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      1
     </month>
     <day>
      22
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10644273
    </articleid>
    <articleid idtype="pii">
     200001180-00006
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

